Combination of Formoterol and Tiotropium in the Treatment of COPD: Effects on Lung Function

REFERENCES

• Rabe K F, Hurd S, Anzueto A, Barnes P J, Buist S A, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532–555
   PubMed Web of Science ®Google Scholar
• Celli B R, Mac Nee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–946
   PubMed Web of Science ®Google Scholar
• Rennard S I. Treatment of stable chronic obstructive pulmonary disease. Lancet 2004; 364: 791–802
   PubMed Web of Science ®Google Scholar
• Barnes P J. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 2004; 117(Suppl 1)24–32
   Google Scholar
• Canning B J, Fischer A. Neural regulation of airway smooth muscle tone. Respir Physiol 2001; 125: 113–127
   PubMedGoogle Scholar
• Ohrui T, Yanai M, Sekizawa K, Morikawa M, Sasaki H, Takishima T. Effective site of bronchodilation by ß-adrenergic and anticholinergic agents in patients with chronic obstructive pulmonary disease: direct measurement of intrabronchial pressure with a new catheter. Am Rev Respir Dis 1992; 146: 88–91
   PubMed Web of Science ®Google Scholar
• Daniel E E, Kannan M, Davis C, Posey-Daniel V. Ultrastructural studies on the neuromuscular control of human tracheal and bronchial muscle. Respir Physiol 1986; 63: 109–128
   PubMedGoogle Scholar
• Rhoden K J, Meldrum L A, Barnes P J. Inhibition of cholinergic neurotransmission in human airways by ß2-adrenoceptors. J Appl Physiol 1988; 65: 700–705
   PubMed Web of Science ®Google Scholar
• Wessler I, Reinheimer T, Brunn G, Anderson G P, Maclagan J, Racké K. ß-adrenoceptors mediate inhibition of (3H)-acetylcholine release from the isolated rat and guinea-pig trachea: role of the airway mucosa and prostaglandins. Br J Pharmacol 1994; 113: 1221–1230
   PubMed Web of Science ®Google Scholar
• Zhang X Y, Olszewski M A, Robinson N E. ß2-Adrenoceptor activation augments acetylcholine release from tracheal parasympathetic nerves. Am J Physiol 1995; 268: L950–956
   PubMed Web of Science ®Google Scholar
• Belvisi M G, Patel H J, Takahashi T, Barnes P J, Giembycz M A. Paradoxical facilitation of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by isoprenaline. Br J Pharmacol 1996; 117: 1413–1420
   PubMed Web of Science ®Google Scholar
• de Haas J RA, Terpstra J S, Zaagsma J, Roffel A F. Enhancement of endogenous acetylcholine and norepinephrine release by prejunctional ß2-adrenoceptors in human isolated bronchi (Abstract). Am J Respir Crit Care Med 1998; 157: A723
   PubMedGoogle Scholar
• Zhang X Y, Zhu F X, Olszewski M A, Robinson N E. Effects of enantiomers of ß2-agonists on ACh release and smooth muscle contraction in the trachea. Am J Physiol 1998; 274: L32–38
   PubMed Web of Science ®Google Scholar
• de Haas J R, Terpstra J S, Van der Zwaag M, Kockelbergh P G, Roffel A F, Zaagsma J. Facilitatory ß2-adrenoceptors on cholinergic and adrenergic nerve endings of the guinea pig trachea. Am J Physiol Lung Cell Mol Physiol 1999; 276: L420–425
   Web of Science ®Google Scholar
• Kume H, Graziano M P, Kotlikoff M I. Stimulatory and inhibitory regulation of calcium-activated potassium channels by guanine nucleotide-binding proteins. Proc Natl Acad Sci USA 1992; 89: 11051–11055
   PubMed Web of Science ®Google Scholar
• Patel H J, Giembycz M A, Keeling J E, Barnes P J, Belvisi M G. Inhibition of cholinergic neurotransmission in guinea pig trachea by NS1619, a putative activator of large-conductance, calcium-activated potassium channels. J Pharmacol Exp Ther 1998; 286: 952–958
   PubMed Web of Science ®Google Scholar
• Brichetto L, Song P, Crimi E, Rehder K, Brusasco V. Modulation of cholinergic responsiveness through the ß-adrenoceptor signal transmission pathway in bovine trachealis. J Appl Physiol 2003; 95: 735–741
   PubMed Web of Science ®Google Scholar
• Dorinsky P M, Reisner C, Ferguson G T, Menjoge S S, Serby C W, Witek T J. Jr. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999; 115: 966–971
   PubMed Web of Science ®Google Scholar
• Easton P A, Jadue C, Dhingra S, Anthonisen N R. A comparison of the bronchodilating effects of a ß-adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med 1986; 315: 735–739
   PubMed Web of Science ®Google Scholar
• Le Doux E J, Morris J F, Temple W P, Duncan C. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD. Chest 1989; 95: 1013–1036
   PubMed Web of Science ®Google Scholar
• COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105: 1411–1419
   PubMed Web of Science ®Google Scholar
• Levin D C, Little K S, Laughlin K R, Galbraith J M, Gustman P M, Murphy D, Kram J A, Hardie G, Reuter C, Ostransky D, McFarland K, Petty T L, Silvers W, Rennard S I, Mueller M, Repsher L H, Zuwallack R L, Vale R. Addition of anticholinergic solution prolongs bronchodilator effect of ß2agonists in patients with chronic obstructive pulmonary disease. Am J Med 1996; 100: 40S–48S
   PubMedGoogle Scholar
• COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997; 112: 1514–1521
   PubMed Web of Science ®Google Scholar
• Friedman M, Serby C W, Menjoge S S, Wilson J D, Hilleman D E, Witek T J. Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635–641
   PubMed Web of Science ®Google Scholar
• Cazzola M, Santangelo G, Piccolo A, Salzillo A, Matera M G, D'Amato G, Rossi F. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994; 7: 103–107
   PubMedGoogle Scholar
• Mahler D A, Donohue J F, Barbee R A, Goldman M D, Gross N J, Wisniewski M E, Yancey S W, Zakes B A, Rickard K A, Anderson W H. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957–965
   PubMed Web of Science ®Google Scholar
• Dahl R, Greefhorst L A, Nowak D, Nonikov V, Byrne A M, Thomson M H, Till D, Della Cioppa G. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778–784
   PubMed Web of Science ®Google Scholar
• Matera M G, Caputi M, Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respir Med 1996; 90: 497–499
   PubMed Web of Science ®Google Scholar
• Sichletidis L, Kottakis J, Marcou S, Constantinidis T C, Antoniades A. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int J Clin Pract 1999; 53: 185–188
   PubMed Web of Science ®Google Scholar
• Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995; 50: 62–66
   PubMed Web of Science ®Google Scholar
• Oren J, Tashkin D P, Gross N J, et al. A pharmacodynamic dose-response study of ipratropium bromide in chronic obstructive pulmonary disease (abstract). Am J Respir Crit Care Med 1998; 157: A802
   Google Scholar
• Cazzola M, Matera M G, Di Perna E, Califano C, D'Amato M, Mazzarella G. Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. Respir Med 1999; 93: 909–911
   PubMed Web of Science ®Google Scholar
• Cazzola M, Di Perna F, Centanni S, Califano C, Donner C F, D'Amato M, D'Amato G. Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease. Thorax 1999; 54: 1083–6
   PubMed Web of Science ®Google Scholar
• van Noord J A, de Munck D R, Bantje T A, Hop W C, Akveld M L, Bommer A M. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878–885
   PubMed Web of Science ®Google Scholar
• D'Urzo A D, De Salvo M C, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G, Kottakis J. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001; 119: 1347–1356
   PubMed Web of Science ®Google Scholar
• Casaburi R, Conoscenti C S. Lung function improvements with once-daily tiotropium in chronic obstructive pulmonary disease. Am J Med 2004; 117(Suppl 1)33–40
   Google Scholar
• Tennant R C, Erin E M, Barnes P J, Hansel T T. Long-acting ß2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?. Curr Opin Pharmacol 2003; 3: 270–276
   PubMed Web of Science ®Google Scholar
• Tashkin D P, Cooper C B. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249–259
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera M G. Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. Chest 2004; 125: 9–11
   PubMed Web of Science ®Google Scholar
• Donohue J F, van Noord J A, Bateman E D, Langley S J, Lee A, Witek T J, Jr., Kesten S, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55
   PubMed Web of Science ®Google Scholar
• Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404
   PubMed Web of Science ®Google Scholar
• Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera M G, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17: 35–39
   PubMed Web of Science ®Google Scholar
• Brashier B, Jantikar A, Maganji M, Raghupathy A, Valsa S, Gokhale P, Mahadik P, Gogtay J, Salvi S S. Addition of formoterol to tiotropium produces better FEV1 and FVC responses when measured over 24 hours following single-dose administration in subjects with moderate-to-severe COPD (Abstract). Chest 2005; 128: 258s
   Google Scholar
• Cazzola M, Noschese P, Salzillo A, De Giglio C, D'Amato G, Matera M G. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 2005; 99: 524–528
   PubMed Web of Science ®Google Scholar
• Di Marco F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006; 100: 1925–1932
   PubMed Web of Science ®Google Scholar
• van Noord J A, Smeets J J, Custers F L, Korducki L, Cornelissen P J. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 639–644
   PubMed Web of Science ®Google Scholar
• van Noord J A, Aumann J L, Janssens E, Smeets J J, Verhaert J, Disse B, Mueller A, Cornelissen P J. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214–222
   PubMed Web of Science ®Google Scholar
• Gaultier C, Reinberg A, Girard E. Circadian rhythms in lung resistance and dynamic lung compliance of healthy children. Effects of two bronchodilatators. Respir Physiol 1977; 31: 169–182
   PubMedGoogle Scholar
• van Noord J A, Aumann J L, Janssens E, Verhaert J, Smeets J J, Mueller A, Cornelissen P J. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509–517
   PubMed Web of Science ®Google Scholar
• Tashkin D, Pearle J, Iezzoni D, Varghese S T. Treatment with formoterol plus tiotropium is more effective than treatment with tiotropium alone in patients with stable chronic obstructive pulmonary disease: Findings from a randomized, placebo-controlled trial. J COPD 2009; 6: 17–25
   PubMedGoogle Scholar
• Vogelmeier C, Kardos P, Harari S, Gans S J, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008; 102: 1511–1520
   PubMed Web of Science ®Google Scholar
• Tashkin D P. COPD treatment with formoterol + tiotropium provides a greater improvement in lung function than treatment with tiotropium alone regardless of concomitant ICS use (abstract). Am J Respir Crit Care Med 2008; 177: A961
   Google Scholar
• Tashkin D P, Pearle J L, Varghese S. Improvement of lung function with coadministered formoterol and tiotropium regardless of smoking status in patients with chronic obstructive pulmonary disease (abstract). Chest 2008; 134: 103S
   Google Scholar
• Terzano C, Petroianni A, Conti V, Ceccarelli D, Graziani E, Sanduzzi A, D'Avelli S. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med 2008; 102: 1701–1707
   PubMed Web of Science ®Google Scholar
• Jarvis S, Ind P W, Shiner R J. Inhaled therapy in elderly COPD patients: time for re-evaluation?. Age Aging 2007; 36: 213–218
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003; 16: 249–254
   PubMedGoogle Scholar
• Gross N J, Kerwin E, Levine B, Kim K T, Denis-Mize K, Hamzavi M, Carpenter M, Rinehart M. Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Pulm Pharmacol Ther 2008, doi:10.1016/j.pupt.2008.07.002
   PubMed Web of Science ®Google Scholar
• Gross N J, Nelson H S, Lapidus R J, Dunn L, Lynn L, Rinehart M, Denis-Mize K. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med 2008; 102: 189–197
   PubMed Web of Science ®Google Scholar
• Donohue J F, Hanania N A, Fogarty C, Campbell S C, Rinehart M, Denis-Mize K. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis 2008; 2: 199–208
   PubMedGoogle Scholar
• Tashkin D P, Littner M, Andrews C P, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008; 102: 479–487
   PubMed Web of Science ®Google Scholar
• Calverley P M, Anderson J A, Celli B, Ferguson G T, Jenkins C, Jones P W, Yates J C, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789
   PubMed Web of Science ®Google Scholar
• Jenkins C R, Jones P W, Calverley P MA, et al. Efficacy of salmeterol/fluticasone propionate by Gold stage of chronic obstructive pulmonary disease: analysis from the randomized, placebo-controlled TORCH study. Respiratory Research 2009; 10: 59, doi: 10.1186/1465-9921-10-59
   PubMed Web of Science ®Google Scholar
• GSK. Final variation assessment report: Seretide Diskus/Viani Diskus Seretide Evohaler/Viani Evohaler (fluticasone propionate/ salmeterol xinafoate), Available at: www.gsk.com/media/pressreleases/2007/2007_07_09_GSK1092.htm Accessed March 25, 2008
   Google Scholar
• Rabe K F, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134: 255–262
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera M G. The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. Respir Med 2007; 101: 957–962
   PubMed Web of Science ®Google Scholar
• Pistolesi M, Camiciottoli G, Paoletti M, et al. Identification of a predominant COPD phenotype in clinical practice. Respir Med 2008; 102: 367–376
   PubMed Web of Science ®Google Scholar
• Cooper C B, Tashkin D P. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ 2005; 330: 640–644
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera M G. To add, or not to add an inhaled corticosteroid in moderate COPD: that is the question. Chest 2008; 134: 223–225
   PubMed Web of Science ®Google Scholar